Overview
ARCT market data
Price History
ARCT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.40 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.27 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.85 – $24.17 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $212.3 · P/B 0.81 · P/S 3.88.
Company news
Arcturus Therapeutics To Present At Canaccord Annual Growth Conference August 11Benzinga · Jul 20, 2026, 8:06 PM
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis TherapyBenzinga · Jul 2, 2026, 3:35 PM
This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For ThursdayBenzinga · Jul 2, 2026, 1:40 PM
This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · Jul 2, 2026, 11:25 AM
Arcturus Therapeutics Collaborates With Thermo Fisher Scientific To Help Support Phase 3 Development And Potential Commercialization Of ARCT-032, Investigational mRNA Therapy For Cystic FibrosisBenzinga · Jul 2, 2026, 11:10 AM
8-K filing — Arcturus Therapeutics Holdings Inc. (ARCT)SEC EDGAR · Jul 2, 2026, 11:05 AM